Steve Lane
QIMR Berghofer, QLD, Australia
- This delegate is presenting an abstract at this event.
I am a clinical haematologist and translational laboratory researcher. My clinical practice and clinical trials focus on novel and targeted therapies for patients with blood cancer. My laboratory researches myeloid blood cancers such as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and the myeloproliferative neoplasms (MPN). These are very aggressive and rapidly fatal blood cancers that are among the most common types of cancer affecting Australians. Our efforts are concentrated on understanding how leukaemia stem cells are able to regenerate leukaemia and cause relapse in patients, even after cytotoxic chemotherapy. The long term goal is to develop treatments that prevent cancer relapse and improve patient survival.
Presentations this author is a contributor to:
Dnmt3a mutations regulate disease progression and response to treatment in acute myeloid leukaemia (136267)
2:10 PM
Steve Lane
Session 1: Stem Cells and Leukaemia
CANCER 2026